TCM
ABBV icon

TimesSquare Capital Management’s AbbVie ABBV Stock Holding History

TimesSquare Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,500
Closed -$842K – 190
2022
Q2 		$842K Buy
5,500
+1,800
+49% +$275K 0.01% 186
2022
Q1 		$600K Buy
+3,700
New +$537K 0.01% 197

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TimesSquare Capital Management's ABBV Position: Q3 2022 in Review

TimesSquare Capital Management sold out of AbbVie (ABBV) in Q3 2022, closing a stake of 5,500 shares — an estimated $842K sold.

TimesSquare Capital Management first reported a position in ABBV in Q1 2022 and held it in 2 quarters. The position peaked at $842K in Q2 2022. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

  • TimesSquare Capital Management reported no remaining AbbVie position as of Q3 2022 after selling out during the quarter.
  • TimesSquare Capital Management sold 5,500 AbbVie shares in Q3 2022, an estimated $842K.
  • TimesSquare Capital Management first reported a position in AbbVie in Q1 2022 and held it in 2 quarters.
  • TimesSquare Capital Management's AbbVie position peaked at $842K in Q2 2022.
  • 2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on TimesSquare Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.